NON-HDL-C MIGHT PREDICT MAJOR ADVERSE CARDIOVASCULAR EVENT OCCURRENCE IN STATIN-NAÏVE PATIENTS FOLLOWING FIRST-TIME...

Area of Science:

• Cardiology
• Lipid Metabolism
• Cardiovascular Disease Research

Background:

• ST-elevation myocardial infarction (STEMI) is a critical cardiovascular event requiring effective risk stratification.
• Lipid parameters, including LDL-C and non-HDL-C, are crucial in managing cardiovascular risk.
• Understanding the prognostic value of specific lipid fractions post-STEMI is essential for patient management.

Purpose of the Study:

• To investigate the impact of non-high-density lipoprotein cholesterol (non-HDL-C) on major cardiovascular events (MACE) following first-time STEMI.
• To compare the predictive significance of non-HDL-C versus LDL-C for MACE in STEMI patients treated with primary PCI and DES.
• To assess the association of baseline lipid profiles with MACE occurrence in this patient cohort.

Main Methods:

• A cohort of 78 patients with first-time STEMI treated with primary PCI and DES implantation were studied.
• Patients were followed for two years to monitor the occurrence of MACE.
• Baseline lipid parameters (total cholesterol, LDL-C, HDL-C, triglycerides, and non-HDL-C) were analyzed for their association with MACE.

Main Results:

• During the 2-year follow-up, 25.6% of patients experienced MACE.
• Significantly higher baseline levels of total cholesterol, LDL-C, and non-HDL-C were observed in patients who had MACE.
• Both non-HDL-C (p=0.007) and LDL-C (p=0.028) were significant predictors of MACE, with non-HDL-C showing a stronger correlation.

Conclusions:

• Baseline non-HDL-C is a more significant predictor of MACE after first-time STEMI than LDL-C.
• Non-HDL-C levels are important for identifying residual cardiovascular risk in STEMI patients.
• Close monitoring of high-risk patients based on non-HDL-C levels is recommended.